SCNI · Scinai Immunotherapeutics Ltd.
Market Cap
$1.70M
Shares
677,581
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.31M
+99.2%
FY2025
Gross Margin
-202.29%
-114.1pp
FY2025
Operating Margin
-575.29%
+737.5pp
FY2025
Diluted EPS
$0.04
-60%
FY2023
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 |
|---|---|---|---|---|---|---|
| $1.31M | $658K | — | — | — | — | |
| $3.96M | $1.24M | — | — | — | — | |
| -$2.65M | -$580K | — | — | — | — | |
| -202.29% | -88.15% | — | — | — | — | |
| $2.52M | $2.53M | $4.51M | $5.3M | $7.63M | — | |
| $4.89M | $8.06M | $9.71M | $11.06M | $10.86M | — | |
| -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.86M | — | |
| -575.29% | -1312.77% | — | — | — | — | |
| -$765K | -$1.33M | $3.21M | $5.27M | $2.66M | — | |
| — | — | $6.5M | $5.8M | $8.21M | — | |
| -$8.31M | $4.8M | -$6.23M | -$5.75M | -$8.17M | — | |
| USD/shares | — | — | $0.04 | $0.10 | -$2.00 | -$330.00 |
| USD/shares | — | — | $0.04 | $0.10 | -$2.00 | -$330.00 |
| shares | 933.95M | 322.55M | 156.26M | 75.41M | 5.65M | — |
| shares | 933.95M | 322.55M | 156.26M | 75.41M | 5.65M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 |
|---|---|
| License | $100,000 |
Key facts
CIK
1611747
CUSIP
09073Q303
13F (30d)
11 filings
11 filers
Visit website
Investor relations